Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 4/2006

01-09-2006 | Topic Paper

What patients take without telling you: holistic approach for BPH

Authors: Jillian L. Capodice, Aaron E. Katz

Published in: World Journal of Urology | Issue 4/2006

Login to get access

Abstract

The use of botanicals and supplements have markedly increased in men that are seeking increased protection against the potential onset and symptomatic relief of lower urinary tract symptoms that are commonly experienced with benign prostatic hyperplasia (BPH). While this implies a positive trend and considers that men are taking a more active role in health and prevention, dialog between the patient and the clinician is often deficient. This may be due to a number of factors including both the patients’ inability to report about the use of certain agents and the clinicians’ inability to ask. Moreover, the sense that natural agents may lack side effects coupled with ineffective communication between the doctor and patient could result in potential adverse interactions. We have performed a comprehensive search of articles published from 1990 to 2005 using the Medline databases in order examine clinical data on the most commonly researched herbs for BPH. We provide a brief update on the state of the research.
Literature
1.
Beckman TJ, Mynderse LA (2005) Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 80(10):1356–1362PubMedCrossRef
2.
3.
Lowe FC (2004) Role of the newer alpha, adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26(11):1701–1713PubMedCrossRef
4.
Brown GA, Sussman DO (2004) A current review of medical therapy for benign prostatic hyperplasia. J Am Osteopath Assoc 104(2 Suppl 2):S11–S16PubMed
5.
Gunther S, Patterson RE, Kristal AR, Stratton KL, White E (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104(1):27–34PubMedCrossRef
6.
Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2(3):212–216PubMedCrossRef
7.
8.
Dvorkin L, Song KY (2002) Herbs for benign prostatic hyperplasia. Ann Pharmacother 36(9):1443–1452PubMedCrossRef
9.
Shoskes DA (2002) Phytotherapy and other alternative forms of care for the patient with prostatitis. Curr Urol Rep 3(4):330–334PubMedCrossRef
10.
Shukla S, Gupta S (2005) Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 53(1):18–32PubMedCrossRef
11.
Greenberg JA, Newmann SJ, Howell AB (2005) Consumption of sweetened dried cranberries versus unsweetened raisins for inhibition of uropathogenic Escherichia coli adhesion in human urine: a pilot study. J Altern Complement Med 11(5):875–878PubMedCrossRef
12.
Awad AB, Gan Y, Fink CS (2000) Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer 36(1):74–78PubMedCrossRef
13.
Cabeza M, Bratoeff E, Heuze I, Ramirez E, Sanchez M, Flores E (2003) Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate. Proc West Pharmacol Soc 46:153–155PubMed
14.
Awad AB, Fink CS, Williams H, Kim U (2001) In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev 10(6):507–513PubMedCrossRef
15.
Berges RR, Windeler J, Trampisch HJ, Senge T (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345(8964):1529–1532PubMedCrossRef
16.
Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80(3):427–432PubMed
17.
Berges RR, Kassen A, Senge T (2000) Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int 85(7):842–846PubMedCrossRef
18.
Wilt TJ, MacDonald R, Ishani A (1999) beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 83(9):976–983PubMedCrossRef
19.
Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev (2):CD001043
20.
Medical Economics (ed) (1998) Physician’s desk reference (PDR) for herbal medicines. Thomson Healthcare, Montvale
21.
Yablonsky F, Nicolas V, Riffaud JP, Bellamy F (1997) Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 157(6):2381–2387PubMedCrossRef
22.
Chatelain C, Autet W, Brackman F (1999) Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 54(3):473–478PubMedCrossRef
23.
Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham H (1998) Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 14(3):127–139PubMedCrossRef
24.
Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G (2002) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev (1):CD001044
25.
Anderson ML (2005) A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro. J Herb Pharmacother 5(1):17–26PubMedCrossRef
26.
Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C (2005) Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 173(2):507–510CrossRef
27.
Habib FK, Ross M, Ho CK, Lyons V, Chapman K (2005) Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114(2):190–194PubMedCrossRef
28.
Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A (2003) BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44(5):549–555PubMedCrossRef
29.
Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC (2004) Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol 45(6):773–779 disucssion 779–780
30.
Zlotta AR, Teillac P, Raynaud JP, Schulman CC (2005) Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 48(2):269–276. Epub 2005
31.
Buck AC (2004) Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172(5 Pt 1):1792–1799PubMedCrossRef
32.
McPartland JM, Pruitt PL (2000) Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc 100(2):89–96PubMed
33.
Wilt T, Ishani A, Mac Donald R (2002) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (3):CD001423
34.
Konrad L, Muller HH, Lenz C, Laubinger H, Aumuller G, Lichius JJ (2000) Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Med 66(1):44–47PubMedCrossRef
35.
Sokeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 86(4):439–442PubMedCrossRef
36.
Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N, Engelmann U (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms–a placebo-controlled, double-blind, multicenter trial. World J Urol 23(2):139–146. Epub 2005
37.
Carbajal D, Molina V, Mas R, Arruzazabala ML (2005) Therapeutic effect of d-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res 31(5–6):193–197PubMed
38.
Fujita R, Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Ueda C, Tajiri H, Kaneko S, Suimi Y, Kondo R (2005) Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol 102(1):107–112PubMedCrossRef
39.
Shibata Y, Kashiwagi B, Arai S, Fukabori Y, Suzuki K (2005) Administration of extract of mushroom Phellinus linteus induces prostate enlargement with increase in stromal component in experimentally developed rat model of benign prostatic hyperplasia. Urology 66(2):455–460PubMedCrossRef
40.
Mannel M (2004) Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 27(11):773–797PubMedCrossRef
41.
Singh YN (2005) Potential for interaction of kava and St. John’s wort with drugs. J Ethnopharmacol 100(1–2):108–113PubMedCrossRef
42.
Bressler R (2005) Herb-drug interactions. Interactions between saw palmetto and prescription medications. Geriatrics 60(11):32–34PubMed
43.
Miller LG (1998) Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158(20):2200–2211PubMedCrossRef
Metadata
Title
What patients take without telling you: holistic approach for BPH
Authors
Jillian L. Capodice
Aaron E. Katz
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 4/2006
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-006-0093-z

Other articles of this Issue 4/2006

World Journal of Urology 4/2006 Go to the issue

Invited Editorial

BPH management at the turn of the twenty-first century: evolution or revolution

Topic Paper

How do I treat and follow my TUNA patients

Original Article

Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?

Topic Paper

First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?

Topic Paper

Transurethral microwave thermotherapy for the treatment of BPH: still a challenger?

Topic Paper

Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin